| Bid price | 365.20 | Open price | 365.30 |
|---|---|---|---|
| Ask price | 366.20 | Prev close | 366.20 |
| High price | 371.40 | Spread | 0.27% |
| Low price | 362.90 | Volume | 516,630 |
Register now for FREE live BTG share prices, BTG stock quotes, charts, trades and FREE BTG company fundamentals, market news and much much more. Why not upgrade to a premium service and get BTG Level 2 Data, indepth research tools and investor commentary for BTG (BGC) and other London Stock Exchange equities.
Register now for FREE BTG share price charts
| Name | BTG | Epic | BGC |
|---|---|---|---|
| Activites | Life Sciences accounted for 70% of fiscal 2008 revenues and Technology Commercialisation, 30% | Reuters | BGC.L |
| ISIN | GB0001001592 | Google Finance | LON:BGC |
| Share Price (p) | 366.20 | Prev. Share Price (p) | 366.20 |
|---|---|---|---|
| Shares in Issue (m) | 327 | Market Cap (£m) | 1,191 |
| PE Ratio (x) | 66.94 | Div per share (p) | 0.00 |
| Div yield (%) | 0.00 | Div cover (x) | |
| EPS (p) | 3.40 | PEG | 3.15 |
Register now for FREE BTG company fundamentals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 21/05/2012 | BUY | Garry Watts | CH | 10,000 |
| 01/09/2011 | EXR | Louise Makin | CEO | 1,455 |
| 02/06/2011 | TIN | Louise Makin | CEO | 367,158 |
| 02/06/2011 | EXR | Louise Makin | CEO | 32,608 |
| 02/06/2011 | SELL | Louise Makin | CEO | 299,766 |
/* */ RNS Number : 8806D BTG PLC 22 May 2012 TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES i 1. Identity of the issuer or the...
Garry Watts, Chairman, bought 10,000 shares in the company on the 21st May 2012 at a price of 360.00p. The Director now holds 10,000 shares representing 0.00% of the shares in issue. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com
/* */ RNS Number : 7849D BTG PLC 21 May 2012 21 May 2012 BTG plc - Directors' interests in the shares of BTG plc Purchase of shares by Garry Watts, Chairman On 21 May 2012, Mr Garry Watts purchased 10,000...
Register now for FREE BTG company news
BTG's upbeat close period update (imo) further confirms the turnaround. With recurring royalty revenues expected to be up by about 5% and R&D spend in line, and a product pipeline to die for, i believe they are cheap, and a real growth stock for the future. Any comments.
-New Company thread - (Ithought it might be useful; to start a "new thread" for the combined company - that's PTI+BTG . . .) - I am assuming the EPIC will remain the same, as I've not heard any different. No specific comment, except I'm glad the deal went smoothly - and - await further...
As most of us already know that the preliminary results of a pivotal European Phase III trial of the BTG's greatest star VARISOLVE were positive. - Overall response rate in patients (435 patients) treated with VARISOLVE® was 83.4%, in line with expectations. - Established that VARISOLVE® is...
Register now for FREE BTG share price discussions